Navigation Links
Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
Date:4/27/2012

M. Catherine Lee, M.D., breast cancer researcher and assistant member at Moffitt Cancer Center, has received a $100,000 grant from General Electric's $100 million healthymagination Challenge to develop genetic tools to investigate an individual's genetic makeup to determine if they are predisposed to develop or resist breast cancer metastasis.

GE's healthymagination grant awarding initiative focuses on "finding new ideas that accelerate innovation in early diagnosis, patient stratification, and the personalized treatment of breast cancer."

Lee's successful proposal, "Heritable Markers of Metastasis in Patients Diagnosed with Breast Cancer," was based on what Lee describes as "significant evidence for specific genetic variations associated with an increased risk of cancer metastasis."

According to Lee, the tumor in breast cancer is not the lethal element. Rather, it is the development and progression of breast cancer to other organs - called metastasis - that determines outcomes and survival. A number of genes and variations of those genes involved in the development of metastatic breast cancer have been identified.

Metastatic breast cancer is deadly. In 2011, an estimated 230,430 women in the United States were diagnosed with breast cancer. Of them, approximately 40,000 will die from metastatic disease.

"We suspect that an individual's genetic makeup can predispose them to develop or resist breast cancer spread," Lee said. "Our approach will be to evaluate genetic variations known as single nucleotide polymorphisms, or SNPs, in patients being treated for breast cancer."

Moffitt collects and banks tissue samples from patients who volunteer to be part of the research. From those tissue banks, the researchers have already identified 150 women treated at Moffitt's Comprehensive Breast Program who developed metastatic disease within five years of follow-up. This group will be compared to a control group of women who did not develop metastatic disease after five years of follow-up.

The task for Moffitt researchers will be to evaluate inherited changes in DNA that are predictive for and identify inherited risk for developing or resisting breast cancer metastasis.

"We hope to identify biologic markers of metastasis to help classify those facing a higher metastasis risk," Lee said. "We also aim to improve therapeutic decision-making and ability to better predict outcomes after a breast cancer diagnosis."

The study falls under Moffitt's mission to offer personalized medicine to patients, a treatment plan by which an individual's disease is treated based on the patient's unique genetic makeup.

"Our ultimate goal is to develop a cheek swab test for patients diagnosed with breast cancer to be able to quickly guide treatment decisions based on their inherited predisposition to develop advanced disease," Lee said.

The Moffitt research team on the grant includes Johnathan Lancaster, M.D., Ph.D.; Ya-Yu Tsai, Ph.D.; and Thomas Sellers, Ph.D., M.P.H., Moffitt executive vice president and director of the Moffitt Research Institute. The research team is also collaborating with laboratories at the National Cancer Institute in Washington, D.C.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Moffitt Cancer Center researchers find more clues to causes of breast cancer
6. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
7. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
8. Moffitt Cancer Center researchers find men less willing to be screened for cancer
9. Moffitt Cancer Center researchers find MK1775 active against sarcomas
10. Moffitt researchers will be strong participants in American Society of Hematology meeting
11. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Virginia (PRWEB) , ... September 20, 2017 , ... ... Flex Pure Clinical Plus Coating System for clients that rely on safety and ... the growth of microorganisms. , Silver has been used for centuries for its ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty Boutique ... Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon ... Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding the ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers from ... Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence based ... Trainers are acknowledged by their peers with accolades and highly prestigious awards. This ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t have the authority ... gouging for their prescription drugs, according to a new comparison of drug plans ... our behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... -- Eli Lilly and Company (NYSE: LLY ... more efficiently focus resources on developing new medicines ... reductions, including those from a U.S. voluntary early ... positions. With the streamlining efforts ... $500 million that will begin to be realized ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
Breaking Medicine Technology: